Evaluation of IL-33 in Patients With the Acute Ischemic Stroke

NCT ID: NCT03948802

Last Updated: 2025-08-15

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 50 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2019-01-01
• Study Completion Date: 2024-03-06

Brief Summary

Aim of the study is to evaluate the usefulness of interleukin 33 in the blood plasma in patients with the acute ischemic stroke of the brain in relation to mode of treatment (thrombolysis, thrombectomy, no treatment), risk factors in correlation with other inflammatory state markers (hsCRP, morphology with smear ). Blood is collected on the first and seventh days of stroke.

The purpose is to clarify utility of IL 33 as a biomarker of acute stroke.

Detailed Description

Stroke is the third most frequent cause of death in highly developed countries (after heart disease and cancer), the main cause of disability in adults and the second most frequent cause of dementia syndromes. The annual incidence of stroke in the general population is approximately 0.2%. The risk of stroke increases with age.

Globally 15 million people are affected each year and 5.5 million die every year for this reason (20% in 30 days and up to 40% in a year from getting ill). In Poland, the incidence of stroke is around 175/100,000 in men and 125/100 in women.It is assumed that the cause of sudden cerebral insufficiency is mainly the embolism coming from the newly formed wall clot forming at the site of the atherosclerotic plaque rupture.

In recent years, the role of inflammatory factors is associated with the occurrence of severe atherosclerotic complications such as stroke or heart attack. Cytokines are glycoproteins that are released by activated cells of various tissues. They have a significant impact on the inflammation processes, they control all phases of the immune response. Interleukin is one of the cytokine groups. This study aims to find a relationship between level of IL 33 concentration and the size of the stroke and neurological deficit.

Blood will be collected on the first and seventh days of stroke for examination of Il 33, blood morphology and hsCRP

Conditions

Ischemic Stroke

Study Design

• Observational Model Type: CASE_CONTROL
• Study Time Perspective: PROSPECTIVE

Study Groups

STROKE GROUP

Cerebral ischemic stroke patients treated.

Interleukine 33 test in blood plasma

Intervention Type: DIAGNOSTIC_TEST

ELISA test for Interleukin 33

CONTROL GROUP

Ambulatory healthy patients

Interleukine 33 test in blood plasma

Intervention Type: DIAGNOSTIC_TEST

ELISA test for Interleukin 33

Interventions

Interleukine 33 test in blood plasma

ELISA test for Interleukin 33

Intervention Type: DIAGNOSTIC_TEST

Eligibility Criteria

Inclusion Criteria

• Age over 18
• Consent on participation
• Diagnosed Ischemic Stroke

Exclusion Criteria

• Active cancer disease
• Kidney failure
• Liver failure
• Pregnancy
• Breastfeeding

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 99 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Jan Biziel University Hospital No 2 in Bydgoszcz

OTHER

Sponsor Role: lead

Responsible Party

Pawel Sokal

Head of Department of Neurosurgery and Neurology

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Paweł Sokal

Role: PRINCIPAL_INVESTIGATOR

Jan Biziel University Hospital Collegium Medicum Nicolaus Copernicus University

Locations

Jan Biziel University Hospital nr 2 Collegium Medicum Nicolaus Copernicus University

Bydgoszcz, , Poland

Countries

Poland

Other Identifiers

JBUH-NN-STROKE-IL33

Identifier Type: -

Identifier Source: org_study_id